Application of a neural network for gentamicin concentration prediction in a general hospital population

Therapeutic Drug Monitoring

Volumn 19, Issue 1, 1997, Pages 25-28

  Corrigan, Brian W ^a   Mayo, Patrick R ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Gentamicin; Neural networks; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL NEURAL NETWORK; CHILD; COMPUTER MODEL; DRUG BLOOD LEVEL; DRUG MONITORING; GENERAL HOSPITAL; HOSPITAL PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GENTAMICINS; HUMANS; INFANT; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 0031410313     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199702000-00004     Document Type: Article

References (16)

1. Erb RJ. Introduction to backpropagation neural network computation [Review]. Pharm Res 1993;10:165-70.
2. Baxt WG. Complexity, chaos and human physiology: the justification for non-linear neural computational analysis. Cancer Lett 1994;77:85-93.
3. Wilding P, Morgan MA, Grygotis AE, Shoffner MA, Rosato EF. Application of backpropagation neural networks to diagnosis of breast and ovarian cancer. Cancer Lett 1994;77:145-53.
4. Pizzi N, Choo LP, Mansfield J, Jackson M, Halliday WC, Mantsch HH. Neural network classification of infrared spectra of control and Alzheimer's diseased tissue. Artificial Intelligence in Medicine 1995;7:67-79.
5. Hamamoto I, Okada S, Hashimoto T, Wakabayashi H, Maeba T, Maeta H. Prediction of the early prognosis of the hepatectomized patient with hepatocellular carcinoma with a neural network. Comput Biol Med 1995;25:49-59.
6. Lapuerta P, Azen SP, LaBree L. Use of neural networks in predicting the risk of coronary artery disease. Comput Biomed Res 1995;28:38-52.
7. Hirst JD, King RD, Sternberg MJ. Quantitative structure-activity relationships by neural networks and inductive logic programming. II. The inhibition of dihydrofolate reductase by triazines. J Comput Aided Mol Des 1994;8:421-32.
8. Manallack DT, Ellis DD, Livingstone DJ. Analysis of linear and nonlinear QSAR data using neural networks. J Med Chem 1994; 37:3758-67.
9. Hussain AS, Yu XQ, Johnson RD. Application of neural computing in pharmaceutical product development. Pharm Res 1991;8: 1248-52.
10. Hussain AS, Johnson RD, Vachharajani NN, Ritschel WA. Feasibility of developing a neural network for prediction of human pharmacokinetic parameters from animal data. Pharm Res 1993; 10:466-9.
11. Veng-Pedersen P, Modi NB. Application of neural networks to pharmacodynamics. J Pharm Sci 1993;82:918-26.
12. Veng-Pedersen P, Modi NB. Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end? J Pharmacokinet Biopharm 1992;20:397-412.
13. Brier ME, Zurada JM, Aronoff GR. Neural network predicted peak and trough gentamicin concentrations. Pharm Res 1995;12:406-12.
14. Zaske D. Aminoglycosides. In: Evans W, Schentag J, Jusko W, eds. Applied Pharmacokinetics. Principles of therapeutic drug monitoring. Vancouver, Applied Therapeutics Inc, 1992:14-1-47.
15. Baxt WG. A neural network trained to identify the presence of myocardial infarction bases some decisions on clinical associations that differ from accepted clinical teaching. Med Decis Making 1994;14:217-22.
16. Egmont-Petersen M, Talmon JL, Brender J, McNair P. On the quality of neural net classifiers. Artificial Intelligence in Medicine 1994;6:359-81.